Boehringer Ingelheim and Click Collaborate on Digital Therapy for Behaviour Modification in Schizophrenia

 Boehringer Ingelheim and Click Collaborate on Digital Therapy for Behaviour Modification in Schizophrenia

Boehringer Ingelheim and Click Collaborate on Digital Therapies for Behavior Modification in Schizophrenia

Shots:

  • Click to receive $500M as up front, funding for research and development activities, clinical, regulatory & commercial milestones along with royalties on sales of CT-155 globally, will lead research and development activities and support Boehringer Ingelheim in global commercialization activities
  • The companies will join their expertise to develop the mobile application, CT-155, which combines multiple clinically validated therapeutic interventions to help schizophrenia patients, modifying their behavior to achieve positive clinical outcomes alone or in combination with pharmaceutical therapies
  • The collaboration will utilize cognitive and neurobehavioral mechanisms delivered through Click’s platform with the goal of reducing cognitive deficits and impaired social functioning in patients with schizophrenia

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post